Rapport Therapeutics Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Rapport Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $59.3. The average 1-year stock price forecast is 26.22% higher than the current stock price, while the lowest is $40 (-14.86%) and the highest is $80 (+70.29%).

Price Target: $59.3 (+26.22%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$40	$59.3	$56	$80
Change	-14.86%	+26.22%	+19.20%	+70.29%

Analyst Ratings

The average analyst rating for Rapport Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	9	10	10	11	12	12
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	10	11	11	12	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Justin Walsh JonesTrading	JonesTrading	Buy Reiterates $42 → $50	Buy	Reiterates	$42 → $50	+6.43%	Aug 6, 2026
Salveen Richter Goldman Sachs	Goldman Sachs	Buy Maintains $58 → $62	Buy	Maintains	$58 → $62	+31.97%	Aug 6, 2026
Danielle Brill Truist Financial	Truist Financial	Buy Maintains $56	Buy	Maintains	$56	+19.20%	Aug 6, 2026
Douglas Tsao H.C. Wainwright	H.C. Wainwright	Buy Reiterates $40	Buy	Reiterates	$40	-14.86%	Aug 6, 2026
Myles Minter William Blair	William Blair	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Aug 5, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

20.00M

Revenue Next Year

n/a

from 20.00M

-100.00%

from 20.00M

EPS This Year

-4.06

from -2.86

EPS Next Year

-4.84

from -4.06

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	20.00M
Operating Income	-5.85M	-36.18M	-83.06M	-125.10M	-205.25M
Net Income	-11.62M	-34.79M	-78.31M	-111.48M	-191.82M
EPS	-	-	-	-2.86	-4.06
Free Cash Flow	-	-17.43M	-44.47M	-54.17M	-190.30M
No. Analysts	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	20.0M
Avg	20.0M
Low	20.0M

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-100.0%
Avg	-100.0%
Low	-100.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-3.85
Avg	-4.06
Low	-4.38

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-